OptimizeRx Co. (NASDAQ:OPRX) Receives Consensus Rating of “Moderate Buy” from Analysts

OptimizeRx Co. (NASDAQ:OPRX) has earned a consensus recommendation of “Moderate Buy” from the nine research firms that are presently covering the stock, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $9.06.

Several research analysts recently commented on OPRX shares. Stifel Nicolaus reduced their target price on shares of OptimizeRx from $13.00 to $8.00 and set a “buy” rating for the company in a report on Thursday, November 14th. Royal Bank of Canada restated a “sector perform” rating and set a $6.00 target price (down previously from $7.00) on shares of OptimizeRx in a report on Wednesday, January 8th. B. Riley reduced their target price on shares of OptimizeRx from $17.00 to $13.00 and set a “buy” rating for the company in a report on Tuesday, December 24th. Roth Mkm restated a “buy” rating and set a $16.00 target price (down previously from $20.00) on shares of OptimizeRx in a report on Thursday, November 14th. Finally, William Blair restated an “outperform” rating on shares of OptimizeRx in a report on Thursday, November 14th.

Insiders Place Their Bets

In related news, CEO William J. Febbo acquired 20,000 shares of the company’s stock in a transaction dated Thursday, December 12th. The shares were bought at an average cost of $5.01 per share, with a total value of $100,200.00. Following the completion of the transaction, the chief executive officer now directly owns 601,253 shares of the company’s stock, valued at $3,012,277.53. This trade represents a 3.44 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 6.10% of the company’s stock.

Hedge Funds Weigh In On OptimizeRx

Large investors have recently modified their holdings of the stock. BNP Paribas Financial Markets grew its stake in shares of OptimizeRx by 189.2% in the third quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company’s stock valued at $28,000 after acquiring an additional 2,414 shares in the last quarter. SBI Securities Co. Ltd. acquired a new stake in OptimizeRx during the fourth quarter worth about $25,000. Quest Partners LLC grew its stake in OptimizeRx by 15,965.6% during the third quarter. Quest Partners LLC now owns 9,800 shares of the company’s stock worth $76,000 after buying an additional 9,739 shares in the last quarter. SG Americas Securities LLC acquired a new stake in shares of OptimizeRx in the 4th quarter valued at approximately $51,000. Finally, Wells Fargo & Company MN boosted its stake in shares of OptimizeRx by 33.3% in the 4th quarter. Wells Fargo & Company MN now owns 11,208 shares of the company’s stock valued at $54,000 after purchasing an additional 2,797 shares in the last quarter. 76.47% of the stock is owned by institutional investors.

OptimizeRx Stock Up 0.8 %

OptimizeRx stock opened at $5.18 on Friday. The stock has a market capitalization of $95.42 million, a PE ratio of -3.89 and a beta of 1.38. OptimizeRx has a twelve month low of $3.78 and a twelve month high of $16.65. The company has a quick ratio of 3.23, a current ratio of 3.23 and a debt-to-equity ratio of 0.29. The company has a 50 day moving average of $5.46 and a 200-day moving average of $6.14.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.